MedPath

LEGION™ Revision Metal Hypersensitivity Study

Not Applicable
Withdrawn
Conditions
Total Knee Replacement Revision
Interventions
Device: LEGION OXINIUM
Device: LEGION Cobalt Chrome
Registration Number
NCT02412813
Lead Sponsor
Smith & Nephew, Inc.
Brief Summary

This is a prospective, randomized, multi-center, metal hypersensitivity study comparing OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty (TKA).

Detailed Description

A total of 230 subjects will be randomized (1:1) to receive either an OXINIUM or cobalt chrome femoral components as part of their LEGION revision procedure. The objective of this study is to assess a lower serum metal ion concentration level in at least one of the three major mLTTs (Co, Cr or Ni) over 5 years in subjects receiving OXINIUM versus Cobalt Chrome femoral components as part of the LEGION Revision Total Knee System.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Subject is skeletally mature
  • Subject is willing to sign and date an IRB/EC approved consent form
  • Subject is a candidate for a revision knee replacement
  • Subject has met an acceptable preoperative medical clearance and is free or treated for cardiac, pulmonary, hematological, infection, or other conditions that would pose excessive operative risk
  • Subject agrees to adhere to the 10-year study visit schedule
Exclusion Criteria
  • Subject with a known metal hypersensitivity
  • Subject requires a known bilateral revision TKA
  • Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation
  • Subject has active infection or sepsis (treated or untreated)
  • Subject with an immunosuppressive disorder
  • Subject has presence of malignant tumor, metastatic, or neoplastic disease
  • Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)
  • Subject has had intra-articular corticosteroid therapy (or any other intra-articular therapy) in the study knee within 3 months of study enrollment
  • Subject has inadequate bone stock to support the device and would require significant augmentation to correct the joint Female subject is of child-bearing age and unwilling to use an approved method of contraception
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to comply with the study
  • Subject is severely overweight (BMI>40)
  • Subject is currently enrolled in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days
  • Subject is facing current or impending incarceration

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LEGION OXINIUM femoral componentLEGION OXINIUM-
LEGION Cobalt Chrome femoral componentsLEGION Cobalt Chrome-
Primary Outcome Measures
NameTimeMethod
Major modified Lymphocyte Transformation Tests (Cobalt, Chromium and Nickel) measurements3,650 Days

Metal hypersensitivity will be concluded if at least one of these three measurements is statistically significant

Secondary Outcome Measures
NameTimeMethod
Revision of LEGION Revision Knee System for any reason at each post-surgical assessment3,650 Days
Changes in mean serum bio-markers from baseline to each subsequent assessment3,650 Days
Minor modified Lymphocyte Transformation Tests (Aluminum, Iron, Molybdenum, Vanadium and Zirconium)3,650 Days

changes in mean mLTTs serum concentration values from baseline to each subsequent assessment

Skin lesion evaluation to measure hypersensitivity3,650 Days
Anteroposterior, lateral and skyline knee views are assessed by radiographs3,650 Days
All adverse event reporting from surgery to 10 year post-surgery3,650 Days
Improves in mean 2011 Knee Society Score (2011 KSS) from baseline to each subsequent assessment3,650 Days

Trial Locations

Locations (3)

Columbia University Medical Center

🇺🇸

New York, New York, United States

Orthopaedic Innovation Centre

🇨🇦

Winnipeg, Manitoba, Canada

Rothman Institute

🇺🇸

Egg Harbor Township, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath